EMA
approval
· 2026-02-09
EMA Authorised: Datroway (datopotamab deruxtecan) — Daiichi Sankyo Europe GmbH
Summary
Datroway (datopotamab deruxtecan) has been authorised in the European Union for breast cancer by Daiichi Sankyo Europe GmbH.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Breast Neoplasms. MAH: Daiichi Sankyo Europe GmbH. Decision date: 09/02/2026